Surgical Outcomes for Perihilar Cholangiocarcinoma with Vascular Invasion.
Aged
Bile Duct Neoplasms
/ mortality
Female
Hepatectomy
/ adverse effects
Hepatic Artery
/ pathology
Humans
Klatskin Tumor
/ mortality
Male
Neoplasm Invasiveness
Neoplasm Metastasis
Portal Vein
/ pathology
Postoperative Complications
Proportional Hazards Models
Retrospective Studies
Treatment Outcome
Perihilar cholangiocarcinoma
Surgical treatment
Survival
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
14
06
2018
accepted:
23
08
2018
pubmed:
12
9
2018
medline:
22
7
2020
entrez:
12
9
2018
Statut:
ppublish
Résumé
To investigate short- and long-term surgical outcomes for patients with perihilar cholangiocarcinoma and vascular invasion. Data from 249 patients who underwent perihilar cholangiocarcinoma surgery between 2000 and 2016 were retrospectively analyzed. Patient evaluations included short-term surgical outcomes following vascular resection and long-term outcomes in cases with histopathological vascular invasion. Mortality was 3.6% overall; 16% for hepatic artery resections, 5.4% for portal vein resections, and 1.7% in the absence of vascular resection (p = 0.029). No between-group differences were observed in the incidence of Clavien-Dindo grade ≥ 3 complications. The factors related to perioperative mortality were hepatic artery resection (odds ratio [OR] = 25.5), right trisectionectomy (OR = 13.0), and central bisectionectomy (OR = 13.8). Multivariate analysis for overall survival identified several prognostic factors: carcinoembryonic antigen level ≥ 5 ng/mL (hazard ratio [HR] = 1.68), poor differentiation (HR = 2.39), distant metastasis (HR = 1.97), and R1 invasive resection (HR = 2.13). Five-year overall survival for patients with portal vein invasion and M0R0/1cis was 35.6%, significantly worse than the 53.4% for patients with no portal vein invasion and M0R/1cis but better than the 0% for patients with portal vein invasion and M1 or R1. Those with hepatic arterial invasion and M0R0/1cis were 24.7%, significantly worse than the 53.4% for patients with no hepatic arterial invasion and M0R0/1cis but significantly better than the 0% for patients with hepatic arterial invasion and M1 or R1. Short-term outcomes for patients with perihilar cholangiocarcinoma and undergoing vascular resection were poor compared to those without vascular resection. Long-term survival in R0M0 disease was more favorable; aggressive surgery is recommended.
Identifiants
pubmed: 30203230
doi: 10.1007/s11605-018-3948-x
pii: 10.1007/s11605-018-3948-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1443-1453Références
Surgery. 2007 May;141(5):581-8
pubmed: 17462457
Eur J Surg Oncol. 2008 Jul;34(7):787-94
pubmed: 18036765
Am J Surg. 2008 Aug;196(2):160-9
pubmed: 18466862
Br J Surg. 2009 Aug;96(8):926-34
pubmed: 19591162
Hepatogastroenterology. 2009 Jul-Aug;56(93):935-42
pubmed: 19760915
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):449-54
pubmed: 19806294
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):476-89
pubmed: 19851704
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):497-504
pubmed: 19859651
Ann Surg. 2010 Feb;251(2):281-6
pubmed: 20054275
Ann Surg. 2010 Jul;252(1):115-23
pubmed: 20531001
J Am Coll Surg. 2011 Apr;212(4):604-13; discussion 613-6
pubmed: 21463797
HPB (Oxford). 2011 Jul;13(7):483-93
pubmed: 21689232
Ann Surg Oncol. 2012 May;19(5):1602-8
pubmed: 21964888
Cancer. 2012 Oct 1;118(19):4737-47
pubmed: 22415526
ANZ J Surg. 2013 Apr;83(4):268-74
pubmed: 22943422
Ann Surg. 2013 Jul;258(1):129-40
pubmed: 23059502
HPB (Oxford). 2014 Jan;16(1):56-61
pubmed: 23461754
J Gastrointest Surg. 2013 Jun;17(6):1107-15
pubmed: 23592188
HPB (Oxford). 2013 Jul;15(7):492-503
pubmed: 23750491
Cell Biochem Biophys. 2014 Jul;69(3):509-16
pubmed: 24510536
J Hepatobiliary Pancreat Sci. 2014 Aug;21(8):525-32
pubmed: 24616395
Eur J Surg Oncol. 2014 May;40(5):489-495
pubmed: 24685155
Surg Today. 2016 Jan;46(1):74-83
pubmed: 25649537
J Hepatobiliary Pancreat Sci. 2015 Mar;22(3):181-96
pubmed: 25691463
J Hepatobiliary Pancreat Sci. 2015 Apr;22(4):249-73
pubmed: 25787274
Surgery. 2015 Nov;158(5):1252-60
pubmed: 26216010
HPB (Oxford). 2015 Dec;17(12):1066-73
pubmed: 26373784
World J Surg. 2016 May;40(5):1211-7
pubmed: 26630938
Hepatobiliary Pancreat Dis Int. 2015 Dec;14(6):626-32
pubmed: 26663011
Int J Clin Exp Med. 2015 Nov 15;8(11):21044-52
pubmed: 26885035
Surgery. 2016 Jun;159(6):1511-1519
pubmed: 26948498
J Surg Res. 2016 May 1;202(1):71-6
pubmed: 27083950
J Hepatobiliary Pancreat Sci. 2016 Jul;23(7):442-8
pubmed: 27207604
Int J Surg. 2016 Aug;32:167-73
pubmed: 27344254
Ann Surg Oncol. 2016 Aug;23(Suppl 4):475-484
pubmed: 27387681
J Surg Oncol. 2017 Aug;116(2):133-139
pubmed: 28411373
Chirurgia (Bucur). 2017 May-Jun;112(3):308-319
pubmed: 28675366
HPB (Oxford). 2018 Apr;20(4):332-339
pubmed: 29169904
J Gastrointest Surg. 2018 Jul;22(7):1204-1212
pubmed: 29512002
Hepatobiliary Pancreat Dis Int. 2018 Apr;17(2):155-162
pubmed: 29636302